FDA clears MiniMed’s tubeless insulin pump
MiniMed has received U.S. Food and Drug Administration (FDA) clearance for its tubeless insulin pump, the MiniMed Fit. This clearance includes patients with type 1 and type 2 diabetes who are 7 years old or older.
The newly cleared automated insulin delivery system can be worn up to seven days without a charge or cartridge change. It was built to be worn on the back of the arm, lower back, upper buttocks, abdomen or thigh. The MiniMed Fit also includes a 300-unit insulin capacity and includes the company’s SmartGuard technology, which adjusts insulin delivery every five minutes.
MiniMed plans on launching the MiniMed Fit in the spring of 2027. The company said it has been increasing its manufacturing capacity and commercial infrastructure to help support that launch.
“People with diabetes shouldn't have to choose between the freedom of tubeless wear and the health outcomes they deserve,” Que Dallara, CEO of MiniMed, said in a statement. “MiniMed Fit brings the technology people trust from MiniMed into a tubeless design that fits their lives. Clearing FDA ahead of schedule is more proof we're executing our strategy. It puts MiniMed Fit in U.S. customers' hands sooner, and the pharmacy channel makes it easier to get.”
According to MiniMed, the device was also designed with the future in mind; it will be compatible with the company’s next-generation fully closed-loop technology once that feature is finalized.
Another sign of a growing trend
Tubeless insulin delivery is gaining momentum as a treatment option throughout the United States. Tandem Diabetes just secured FDA clearance for its own Tandem Mobi insulin pump to be used as tubeless automated insulin delivery system. The market’s other tubeless option, the Omnipod 5, has been available for years. These systems all have different settings and features.
MiniMed has been around for more than four decades. It was Medtronic’s diabetes business before officially separating from the medtech company this year.
